THE TAPE

First Tracks Biotherapeutics, Inc. Ordinary Shares

$46.56▼ −1.15%
Last close
Relative strength
—RS
Not ranked yet
Developing
+135.6%
six months against Pharmaceutical Preparations
147-session range
−15.0%
from the high
$14.72$54.78
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
No US GAAP filings to read.
Why it is on no screen

TRAX is off the screens on one check: a base has formed.

A base has formedNo pause of 3 weeks or more inside the last 24 weeks.
Long enough to countNeeds a base first.
Shallow enoughNeeds a base first.
Close to its pivotNeeds a base first.
Relative strengthNot ranked yet — too little history.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter

No 200-day line: this stock has under a year of daily history.

Support and resistance
Support below
$41.57
-10.7% · tested 8× · last 25 sessions ago
Resistance above
$47.18
+1.3% · tested 6× · last 12 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

First Tracks Biotherapeutics, Inc. Ordinary Shares is not on any of the screens right now. Its relative strength rating is not ranked yet, and it sits in Pharmaceutical Preparations.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+29.4%
Three months against its industry
+22.6%
Six months against its industry
+135.6%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 7.3% either way across its last 2 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Pulled back while its group leadsTape · 2026-11-14
3 lower closes in a leading group, 50d held, at 47.10
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
GappedTape · 2026-11-11
+5.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-07
+5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-7.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-05
+5.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Reported resultsFiling · 2026-11-04
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Pulled back while its group leadsTape · 2026-11-03
3 lower closes in a leading group, 50d held, at 45.05
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
Tightening after a sharp runTape · 2026-11-03
range halved after a +43% thrust, at 45.05
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect
Strong buy3
Buy9
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) — The Tape